Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Aug;26(4):326-333.
doi: 10.4103/aian.aian_254_23. Epub 2023 Aug 28.

Alzheimer's Disease: Treatment Today and Tomorrow

Sankar P Gorthi  1 , Dulari Gupta  1
Affiliations

Alzheimer's Disease: Treatment Today and Tomorrow

Sankar P Gorthi et al. Ann Indian Acad Neurol. 2023 Jul-Aug.

Abstract

Background and aims: The scope of treatment in Alzheimer's Disease has widened in recent times with FDA approval of new drugs. This review looks at established treatments in AD as well as critically analyses the newer drugs available.

Methods: Data in this review was gathered from PubMed; Google Scholar and MEDLINE from January-March 2023. Search words used were 'Alzheimer's Disease treatment' and 'Dementia treatment'.

Results: Older time tested drugs like Acetyl Choline Receptor Inhibitors and NMDA Receptor antagonists remain the mainstay of pharmacological treatment in AD. Despite a lot of excitement about newer FDA approved drugs; we have to be cautious in their use. Aducanumab showed good reduction in CSF amyloid levels (biomarker of AD); but this did not necessarily translate into better clinical outcomes of patients.

Conclusion: Despite the recent advances and approval of drugs in treatment of AD, we have to exhibit caution while prescribing these drugs. Even with a sound mechanism of action, these drugs do not always show improvement in clinical outcomes. More clinical trials are required for development of drugs in treatment of AD which explore various different mechanisms of action.

Keywords: Alzheimer’s disease; advances; treatment.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. The Tacrine Collaborative Study Group. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 1992;327:1253–9. - PubMed
    1. Alzheimer's Disease and Related Dementias. National Institute on Aging. 2023. [[Last accessed on 2023 Mar 07]]. Available from: https://www.nia.nih.gov/health/alzheimers .
    1. Clinical Benefits Associated with a Transdermal Patch for Dementia. 2011 Jul 22. [[Last accessed on 2023 Mar 07]]. Available from: https://touchneurology.com/alzheimersdisease-dementia/journal-articles/c...
    1. Clinical Benefits Associated with a Transdermal Patch for Dementia. 2011 Jul 22. [[Last accessed 2023 Mar 06]]. Available from: https://touchneurology.com/alzheimersdisease-dementia/journal-articles/c...
    1. Lefèvre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther. 2008;83:106–14. - PubMed